When lost quickly, the underlying scaffolding disappears, and the skin as well as the supporting collagen and elastin may not adapt in time, leading to sagging, deeper folds, and a deflated appearance often described as Ozempic face. Common facial changes associated with GLP-1-driven weight loss include: Sunken cheeks and temples Sagging jowls and jawline Deepening of nasolabial folds (smile lines) Downturned corners of the mouth Flattened or elongated lips Excess skin and loss of facial volume These changes result not only from fat loss but also from the skins decreased elasticity that occurs with both aging and accelerated weight reduction
MORE: Newly approved weight-loss pills could expand access to GLP-1s The study, published Wednesday in the journal Nature, surveyed more than 27,000 people in the 23andMe genetic database about their responses to the GLP-1 drugs semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound)
While tirzepatide has been investigated in type 1 diabetes contexts, its GLP-1 and GIP receptor agonism affects pancreatic function in ways that may interact unpredictably with pancreatic autoimmune processes
While effective, phentermine is just one of several alternatives to Semaglutide for weight loss, and understanding where it fits best is key
What I tell my patients is this: the medication isnt the villain here
.png)
